Physician profile
Mark S Steen
NPI 1306929906
$3,766.65
in general payments reported to CMS, 2019-2025
19 companies · $38.31 in 2025
The $38.31 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.80 · 2020: $2,323 · 2021: $326 · 2022: $416 · 2023: $248 · 2024: $381 · 2025: $38.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $667.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $2,098.53 | 2020 | |
| Shockwave Medical, INC | $270.01 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $181.61 | 2022 | |
| Biotronik INC. | $155.37 | 2020 | |
| Amgen INC. | $151.64 | 2022-2025 | Repatha |
| Merck Sharp & Dohme LLC | $138.14 | 2023-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.63 | 2022-2024 | Jardiance |
| Penumbra, INC. | $125.00 | 2021 | |
| Boston Scientific Corporation | $101.28 | 2021-2025 | Watchman Access System |
| Janssen Pharmaceuticals, INC | $90.59 | 2021-2023 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $88.51 | 2019-2024 | Brilinta, Farxiga |
| Getinge USA Sales, LLC | $68.84 | 2020 | |
| Pfizer INC. | $43.04 | 2024 | |
| Novartis Pharmaceuticals Corporation | $28.64 | 2021-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $24.50 | 2024 | Arcalyst |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $20.04 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.37 | 2021 | |
| Novo Nordisk INC | $15.87 | 2024 | Rybelsus, Ozempic |
| Esperion Therapeutics, INC. | $14.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Steen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.